MedTrace Logo

S1+ Paclitaxel (IV&IP) + Bevacizumab (IP) Versus S1+Oxaliplatin as First-line Treatment in Gastric Cancer With Malignant Ascites

NCT03990103 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2019-06-19

No results posted yet for this study

Summary

The purpose of this study is to compare the efficacy of S1 plus paclitaxel (intravenous injection \& intraperitoneal injection) plus bevacizumab (intraperitoneal injection) vs. S1 plus oxaliplatin intravenous injection as first-line treatment in gastric or gastroesophageal junctional adenocarcinoma with malignant ascites.

Conditions

  • Metastatic Gastric Adenocarcinoma

Interventions

DRUG

S1

80-120 mg/day, PO, D1-14, every 21 days

DRUG

Paclitaxel

20 mg/m2/day, IP, D1-3; 50 mg/m2, IV, D1; 70 mg/m2, IV, D8; every 21 days

DRUG

Bevacizumab

200 mg, IP, D1, every 21 days

DRUG

Oxaliplatin

130 mg/m2, IV, D1, every 21 days

Sponsors & Collaborators

  • China Medical University, China

    lead OTHER

Principal Investigators

  • Yunpeng Liu, M.D. · China Medical University, China

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-01
Primary Completion
2021-04-30
Completion
2022-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03990103 on ClinicalTrials.gov